Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study - Concepedia

Concepedia

Publication | Closed Access

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study

36

Citations

0

References

2005

Year

Alan F. List, G Dewald, Jeffrey Bennett, A. Giagounadis, Azra Raza, E. Feldman, Benjamin Powell, Peter L. Greenberg, Jerome B. Zeldis, Robert Knight

Journal of Clinical Oncology

Hematological MalignancyMyelodysplastic SyndromeHematologyPathologyMedicineMulticenter Mds-003 StudyMyeloid Neoplasia

Abstract

5